Pfizer, Merck trial antiviral combos amid concerns over resistance to COVID-19 pills

Summary by Ground News
FDA greenlighted Paxlovid and molnupiravir as the first oral COVID-19 therapies for at-home use last month. However, the mutations that allow viruses to evade the antivirals are a real danger for drugs. The researchers from Pfizer (PFE) and Merck (MRK) have rebuffed such fears noting that they did not see drug resistance during their trials.
4 months ago

News Articles

Seeking Alpha

Pfizer, Merck trial antiviral combos amid concerns over resistance to COVID-19 pills

Pfizer (PFE) and Merck (MRK), the developers of the first oral medications for COVID-19 in the U.S., are advancing combination studies for their antiviral therapies as experts flag the...

4 months ago·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

100% of the sources are Center
Seeking Alpha
C 100%
Untracked bias
See less detail